相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The nose has it: Opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters
Steve Chung et al.
EPILEPSY & BEHAVIOR REPORTS (2023)
Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly An integrated analysis
Sarina Tanimoto et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2023)
Intranasal drug delivery: opportunities and toxicologic challenges during drug development
Lea-Adriana Keller et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2022)
Effect of Different Absorption Enhancers on the Nasal Absorption of Nalmefene Hydrochloride
Ting Zhang et al.
AAPS PHARMSCITECH (2022)
Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs
Andrew Lofts et al.
CNS DRUGS (2022)
Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action
Wade Cooper et al.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2022)
Intranasal Delivery of Darunavir-Loaded Mucoadhesive In Situ Gel: Experimental Design, In Vitro Evaluation, and Pharmacokinetic Studies
Anroop B. Nair et al.
GELS (2022)
Nano-lipidic formulation and therapeutic strategies for Alzheimer's disease via intranasal route
Shourya Tripathi et al.
JOURNAL OF MICROENCAPSULATION (2021)
Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters
James Cloyd et al.
EPILEPSIA (2021)
Lack of observed impact of history or concomitant treatment of seasonal allergies or rhinitis on repeated doses of diazepam nasal spray administered per seizure episode in a day, safety, and tolerability: Interim results from a phase 3, open-label, 12-month repeat-dose safety study
Blanca Vazquez et al.
EPILEPSY & BEHAVIOR (2021)
Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
James W. Wheless et al.
EPILEPSIA (2021)
Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: Results from an exit survey of a phase 3, open-label, repeat-dose safety study
Patricia Penovich et al.
EPILEPSY & BEHAVIOR (2021)
Improvement of Intranasal Drug Delivery with Intravail(R) Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System
Adrian L. Rabinowicz et al.
DRUGS IN R&D (2021)
Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers
R. Edward Hogan et al.
EPILEPSIA (2020)
Naloxone Administration by Untrained Community Members
William Eggleston et al.
PHARMACOTHERAPY (2020)
Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: A phase 1, open-label study
Robert Edward Hogan et al.
EPILEPSIA (2020)
Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose
Philip Krieter et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose
Philip Krieter et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study
Richard B. Lipton et al.
HEADACHE (2018)
Evaluation of intranasal delivery route of drug administration for brain targeting
Franciska Erdo et al.
BRAIN RESEARCH BULLETIN (2018)
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
Sagar Munjal et al.
JOURNAL OF HEADACHE AND PAIN (2017)
A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults
Sagar Munjal et al.
HEADACHE (2016)
Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles
Deepak Sharma et al.
AAPS PHARMSCITECH (2015)
Analytical Challenges and Regulatory Requirements for Nasal Drug Products in Europe and the U.S.
Sabrina Trows et al.
Pharmaceutics (2014)
A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers
Suresh K. Agarwal et al.
EPILEPSY RESEARCH (2013)
High efficiency intranasal drug delivery using Intravail® alkylsaccharide absorption enhancers
Edward T. Maggio et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2013)
Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review
Per Gisle Djupesland
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2013)
Anatomical and Histological Factors Affecting Intranasal Drug and Vaccine Delivery
Sveinbjorn Gizurarson
CURRENT DRUG DELIVERY (2012)
Reestablishment of the Nasal Permeability Barrier to Several Peptides Following Exposure to the Absorption Enhancer Tetradecyl-β-D-Maltoside
John J. Arnold et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: Results of the INDEX trial
AJ Dowson et al.
HEADACHE (2005)
Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin
F Mustafa et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells
JJ Arnold et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis
GA Davis et al.
CLINICAL DRUG INVESTIGATION (2004)
Nasal administration of low molecular weight heparin
J Arnold et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2002)
Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats
F Ahsan et al.
PHARMACEUTICAL RESEARCH (2001)
Effects of pH and dose an nasal absorption of scopolamine hydrobromide in human subjects
S Ahmed et al.
PHARMACEUTICAL RESEARCH (2000)
Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts
P Tengamnuay et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2000)